Treatment of AML cells with MBZ resulted in downregulation of intracellular protein levels of GLI1/GLI2 transcription factors and reduced the GLI promoter activity in luciferase-based reporter assays. The gene discussed is GLI1; the disease is acute myeloid leukemia.